Citi Maintains Buy on Lincare Holdings (LNCR)

Citi is out with its report on Lincare Holdings LNCR, maintaining Buy. In a note to clients, Citi writes, "We rate LNCR Buy/Medium Risk (1M) due to a recurring history of government reimbursement reductions. That said, we believe LNCR may be unmolested by government cuts for at least 2011-2012, perhaps longer. We believe the stock can garner a mid-teens multiple for its 20-30% organic EPS growth. We continue to believe that LNCR is a near and long-term winner from the consolidation of the industry that is underway, and we still believe the shares are under-valued." Citi has a $41 PT on LNCR. Shares of LNCR closed Tuesday at $29.91, up 1.12% from Monday's close.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsCitiHealth CareHealth Care ServicesLincare Holdings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!